Pharming Group N.V. Files 6-K with Press Release
Ticker: PHAR · Form: 6-K · Filed: Jan 21, 2025 · CIK: 1828316
| Field | Detail |
|---|---|
| Company | Pharming Group N.V. (PHAR) |
| Form Type | 6-K |
| Filed Date | Jan 21, 2025 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $250M |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
Pharming Group N.V. dropped a 6-K with a press release on Jan 21, 2025. Details TBD.
AI Summary
Pharming Group N.V. filed a Form 6-K on January 21, 2025, to furnish a press release dated January 21, 2025, as Exhibit 99.1. The filing does not contain specific financial figures or operational details beyond the submission of this press release.
Why It Matters
This filing indicates Pharming Group N.V. is providing updated information to the SEC, likely related to recent business developments or announcements shared in the press release.
Risk Assessment
Risk Level: low — This is a routine filing to submit a press release, with no immediate indication of significant new risks or negative developments.
Key Players & Entities
- Pharming Group N.V. (company) — Registrant
- January 21, 2025 (date) — Press Release Date
- 001-39822 (other) — SEC File Number
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to furnish a press release dated January 21, 2025, as Exhibit 99.1.
What is the filing date of this Form 6-K?
This Form 6-K was filed on January 21, 2025.
What is the SEC file number for Pharming Group N.V.?
The SEC file number for Pharming Group N.V. is 001-39822.
Where is Pharming Group N.V. located?
Pharming Group N.V.'s principal executive offices are located at Darwinweg 24, 2333 CR Leiden, The Netherlands.
Does this filing include a Form 20-F or Form 40-F?
The filing indicates that the registrant files annual reports under cover of Form 20-F.
Filing Stats: 1,866 words · 7 min read · ~6 pages · Grade level 12.8 · Accepted 2025-01-21 06:04:14
Key Financial Figures
- $250M — and biology. Mr. Chouraqui raised over $250M and attracted world-renowned investors.
Filing Documents
- pharmingtonominatebiopharm.htm (6-K) — 38KB
- logo_greyxoriginalx.jpg (GRAPHIC) — 112KB
- logo_pharmingxoriginal.jpg (GRAPHIC) — 18KB
- 0001828316-25-000002.txt ( ) — 206KB
Forward-looking Statements
Forward-looking Statements This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as "aim", "ambition", anticipate'', believe'', could'', estimate'', expect'', goals'', intend'', may'', "milestones", objectives'', outlook'', plan'', probably'', project'', risks'', "schedule", seek'', should'', target'', will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2023 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred t